0001104659-23-080099.txt : 20230711
0001104659-23-080099.hdr.sgml : 20230711
20230711203026
ACCESSION NUMBER: 0001104659-23-080099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230707
FILED AS OF DATE: 20230711
DATE AS OF CHANGE: 20230711
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Deliargyris Efthymios
CENTRAL INDEX KEY: 0001751617
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 231083088
MAIL ADDRESS:
STREET 1: C/O PLX PHARMA,INC.8285 EL RIO STREET
STREET 2: SUITE 210
CITY: HOUSTON
STATE: TX
ZIP: 77054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 305 COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 305 COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
4
1
tm2321021-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-07-07
0
0001175151
Cytosorbents Corp
CTSO
0001751617
Deliargyris Efthymios
C/O CYTOSORBENTS CORPORATION
305 COLLEGE ROAD EAST
PRINCETON
NJ
08540
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-07-07
4
A
0
55000
0
A
331648
D
Stock Option (right to buy)
3.53
2023-07-07
4
A
0
78000
0
A
2033-07-07
Common Stock
78000
78000
D
Stock Option (right to buy)
3.53
2023-07-07
4
A
0
40000
0
A
2033-07-07
Common Stock
40000
40000
D
These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
Includes (a) (i) 120,000 RSUs granted on April 9, 2020 that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan");
(continued from footnote 2) (b) the following RSUs: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (these RSUs cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date); (b) 55,000 RSUs granted on August 10, 2022 and unvested on the date hereof (these RSUs vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and (c) 55,000 RSUs granted on July 7, 2023 and reported on this Form 4; and
(continued from footnote 3) (c) 46,981 shares of Common Stock owned by the reporting person.
These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
/s/ Kathleen P. Bloch attorney-in-fact for Efthymios Deliargyris
2023-07-11